JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.